Heart Disease Clinical Trials in Baltimore

Showing 181-200 of 583 trials

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

NCT05284617

This is a Phase 2A, randomized, parallel-group, placebo-controlled, double-blind, within subject dose escalation trial with 3 dose levels of HU6 and placebo. Subjects will be randomized (1:1) either to HU6 or placebo. Two dose levels will be administered in sequential order (150 mg daily followed by 300 mg daily), each for 20 days, to reach the third and highest dose of 450 mg daily if safety and tolerability are demonstrated at the lower 2 preceding doses. Administration of the 450 mg high dose will continue for a total of 94 days, with a safety follow-up visit within \~14 days of the last dose.

Heart Failure With Preserved Ejection Fraction

Rivus Pharmaceuticals, Inc.67 participantsStarted Oct 2022

Beverly Hills, California, United States • Torrance, California, United States • Hialeah, Florida, United States +12 more locations

COMPLETEDPhase 3< 1 mile

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

NCT03860935

Phase 3 efficacy and safety study to evaluate acoramidis (AG10) HCl 800 mg administered orally twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

AmyloidosisAmyloid CardiomyopathyTransthyretin Amyloidosis+2 more

Eidos Therapeutics, a BridgeBio company632 participantsStarted Mar 2019

Los Angeles, California, United States • Santa Monica, California, United States • Aurora, Colorado, United States +101 more locations

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Heart Disease Trials in Other Cities

Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors

Breethe Abiomed Recovery RegisTry (BART)

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Creating A Cardiorenal Multidisciplinary Team for Management HF and CKD Patients

Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

REmodeling the Left Ventricle With Atrial Modulated Pacing

Physiologic Pacing Registry

Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator

Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT

Dapagliflozin at Discharge on Hospital Heart Failure Readmission

Use of Oxandrolone to Promote Growth in Infants With HLHS

Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)

Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease

Rivet PVS Therapy in Group 2 PH-HFpEF

Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Other Conditions in Baltimore